Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) declines year over year

Q2 FY2026 weighted avg shares (diluted) of 106.8M shares fell 1.7% year over year, ahead of the -4.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at -1.5% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -1.7% holds above the trailing-twelve-month pace of -4.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
106.8M-0.8% QoQ
Last fiscal yearDec 2025
108.6M-5.6% YoY
LTMJun 2026
107.3M-4.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.7%——
1 year-5.6%——
3-year CAGR-1.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
108.6M USD
Year-over-year change
-5.6%
4-year CAGR
-0.8%

Weighted Avg Shares (Diluted) vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's LTM Jun 2026 weighted avg shares (diluted) of 107.3M shares is the 8th highest of the 9 companies compared; the peer median is 590.25M shares.
  • Its year-over-year change of -4.6% is the lowest of 8, against a peer median of +0.3%.
  • Over three fiscal years its annual growth of -1.5% compares with a peer median of +0.1%.
REGN Competitors Peer median
Weighted Avg Shares (Diluted) for REGN and competitors
Company Period LTM YoY 3-year CAGR
NVSNovartis AGLTM Jun 20261.92B -3.4%-3.8%
AZNAstraZeneca PLCLTM Sep 20261.56B +0.0%+0.0%
GILDGilead Sciences, Inc.LTM Jun 20261.25B -0.5%-0.2%
GMABGenmab A/SLTM Jun 2026637.25M —-1.7%
AMGNAmgen Inc.LTM Jun 2026543.25M +0.3%+0.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026200.88M +19.9%+31.3%
BIIBBiogen Inc.LTM Jun 2026147.73M +1.2%+0.2%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026107.3M -4.6%-1.5%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
Peer median (excluding REGN) 590.25M+0.3%+0.1%

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.07B12.17B13.12B14.2B14.34B
Cost of Revenue2.72B1.71B2.24B1.97B2.1B
Gross Profit13.35B10.47B10.87B12.23B12.24B
Gross Margin83.1%86.0%82.9%86.1%85.4%
Research & Development2.62B3.06B3.99B5.23B5.85B
Selling, General & Admin1.82B2.12B2.54B2.95B2.7B
Operating Expenses4.4B5.08B6.52B8.24B8.66B
Depreciation & Amortization286.2M341.4M421M482.9M543.7M
EBITDA9.67B5.26B4.69B5.32B5.82B
EBITDA Margin60.2%43.2%35.8%37.4%40.6%
Operating Income8.95B5.39B4.35B3.99B3.58B
Operating Margin55.7%44.2%33.2%28.1%24.9%
Interest Income0160.1M495.9M711.4M716.8M
Interest Expense57.3M59.4M73M55.2M43.8M
Other Income / Expenses379M(526.8M)(149.3M)789.2M1.65B
Income Before Tax9.33B4.86B4.2B4.78B5.23B
Pre-Tax Margin58.0%39.9%32.0%33.7%36.5%
Income Tax Expense1.25B520.4M245.7M367.3M725.8M
Net Income8.08B4.34B3.95B4.41B4.5B
Net Margin50.2%35.6%30.1%31.1%31.4%
EPS (Basic)76.4040.5137.0540.9043.07
EPS (Diluted)71.9738.2234.7738.3441.48
Weighted Avg Shares105.7M107.1M106.7M107.9M104.6M
Weighted Avg Shares (Diluted)112.2M113.5M113.7M115.1M108.6M

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.